

AMENDMENTS TO THE CLAIMS:

Amend the claims as follows:

1. (Currently Amended) A cytoplasmic transduction peptide characterized in that said cytoplasmic transduction peptide has a cell membrane transduction potential; where a cell is treated with said cytoplasmic transduction peptide for a period of time and then treated with a protease, a cell membrane transduction by said cytoplasmic transduction peptide continues to occur; and after said cell membrane transduction, said cytoplasmic transduction remains in the cytoplasm of said cell, wherein said cytoplasmic transduction peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1, 2 and 13.

Claims 2 -16. (canceled)

17. (Withdrawn - Currently amended) The cytoplasmic transduction peptide according to claim [[16]] 1, wherein said cytoplasmic transduction peptide comprises an amino acid sequence ~~selected from the group consisting of~~ SEQ ID ~~NO:1~~NOs:1 and 13.

18. (Previously Presented) A nucleic acid molecule encoding the cytoplasmic transduction peptide according to claim 1.

19. (Previously Presented) A cytoplasmic transduction system comprising the cytoplasmic transduction peptide according to claim 1 and a biologically active molecule covalently linked to said peptide.

20. (Original) A method for delivering a biologically active molecule into a cytoplasm of a cell, which comprises contacting the cytoplasmic transduction system according to claim 19 to said cell.

21. (Original) A method for delivering a biologically active molecule into a cytoplasm of cells of an individual, which comprises administering the cytoplasmic transduction system according to claim 19 to said individual.

22. (Original) The method according to claim 21, wherein said cell is liver cell or lymphoid cell.